Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H39N3O3 |
| Molecular Weight | 465.6276 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)C2=CC(O)=CC=C2)NC(=O)[C@H]3CC4=C(CN3)C=C(O)C=C4
InChI
InChIKey=ZLVXBBHTMQJRSX-VMGNSXQWSA-N
InChI=1S/C28H39N3O3/c1-18(2)26(30-27(34)25-13-20-8-9-24(33)12-21(20)15-29-25)17-31-11-10-28(4,19(3)16-31)22-6-5-7-23(32)14-22/h5-9,12,14,18-19,25-26,29,32-33H,10-11,13,15-17H2,1-4H3,(H,30,34)/t19-,25+,26+,28+/m0/s1
| Molecular Formula | C28H39N3O3 |
| Molecular Weight | 465.6276 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:49:12 UTC 2023
by
admin
on
Sat Dec 16 01:49:12 UTC 2023
|
| Record UNII |
3C6FZ6UXC8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
361444-66-8
Created by
admin on Sat Dec 16 01:49:12 UTC 2023 , Edited by admin on Sat Dec 16 01:49:12 UTC 2023
|
PRIMARY | |||
|
JDTIC
Created by
admin on Sat Dec 16 01:49:12 UTC 2023 , Edited by admin on Sat Dec 16 01:49:12 UTC 2023
|
PRIMARY | This study has been terminated.(No further subjects will be enrolled due to adverse events.) | ||
|
3C6FZ6UXC8
Created by
admin on Sat Dec 16 01:49:12 UTC 2023 , Edited by admin on Sat Dec 16 01:49:12 UTC 2023
|
PRIMARY | |||
|
DTXSID70433301
Created by
admin on Sat Dec 16 01:49:12 UTC 2023 , Edited by admin on Sat Dec 16 01:49:12 UTC 2023
|
PRIMARY | |||
|
9956146
Created by
admin on Sat Dec 16 01:49:12 UTC 2023 , Edited by admin on Sat Dec 16 01:49:12 UTC 2023
|
PRIMARY | |||
|
JDTIC
Created by
admin on Sat Dec 16 01:49:12 UTC 2023 , Edited by admin on Sat Dec 16 01:49:12 UTC 2023
|
PRIMARY | JDTic is a selective, long-acting ("inactivating") antagonist of the .KAPPA.-opioid receptor (KOR). JDTic is a 4-phenylpiperidine derivative, distantly related structurally to analgesics such as pethidine and ketobemidone, and more closely to the MOR antagonist alvimopan. In addition, it is structurally distinct from other KOR antagonists such as norbinaltorphimine. | ||
|
JDTIC
Created by
admin on Sat Dec 16 01:49:12 UTC 2023 , Edited by admin on Sat Dec 16 01:49:12 UTC 2023
|
PRIMARY | Kappa Antagonist JDTic in Phase 1 Clinical Trial |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
When JDTic was administered either s.c. or p.o. 24 h before the selective KOP (kappa)-opioid receptor agonist, enadoline, AD(50s) of 4.1 and 27.3, respectively, were obtained. A time-course study of JDTic versus enadoline indicated significant antagonist p.o. activity up to 28 days.
|
